Wednesday, 8 July 2026
Endometriosis diagnosis tests recommended, Daraxonrasib review for pancreatic cancer, Insulin cost analysis post-cap
- 01
New Tests May Accelerate Endometriosis Diagnosis in Primary Care
Two non-invasive tests have been recommended by the National Institute for Health and Care Excellence (NICE) to expedite the diagnosis of endometriosis in primary care. These tests aim to address the lengthy diagnosis times, which currently average over nine years in the UK, and up to 11 years for women from ethnically diverse communities. Endometriosis affects approximately one in 10 women of reproductive age, making it a significant health concern. The tests could improve women's health management by reducing the time to diagnosis.
via BMJ
- 02
EMA fast-tracks daraxonrasib review for pancreatic cancer
The European Medicines Agency's human medicines committee has initiated a phased review of daraxonrasib, aimed at treating metastatic pancreatic cancer. This decision follows a phase 3 study comparing daraxonrasib with chemotherapy in patients who had previously received treatment. Patients with metastatic pancreatic cancer face limited options and a poor prognosis, highlighting the significant unmet medical need. The phased review process is expected to expedite the assessment timeline, potentially leading to earlier access to this promising treatment.
- 03
Analysis of Insulin Costs Post-Inflation Reduction Act
An interrupted time series analysis examined Medicare Part D data from January 2021 to December 2023, focusing on insulin costs and usage following the $35 cap on out-of-pocket insulin expenses introduced by the Inflation Reduction Act. The study specifically looked at the impact on insulin users who previously faced high out-of-pocket costs. This analysis provides insights into how the cap may affect medication access and affordability for diabetes patients.
via JAMA
- 04
FDA Approves First Treatment for Chronic Hepatitis Delta Virus
The US Food and Drug Administration (FDA) has approved the first treatment for chronic hepatitis delta virus infection. This liver disease occurs exclusively in individuals infected with hepatitis B virus. The approval represents a significant advancement in the management of liver diseases, particularly for affected patients.
via JAMA
- 05
Surgeon General’s Advisory Addresses Excessive Screen Use in Children
The US Department of Health and Human Services Office of the Surgeon General issued an advisory regarding the dangers of excessive screen use among children and adolescents. This advisory raises awareness about the potential harms associated with high screen time in younger populations. Currently, there is no confirmed US surgeon general in office.
via JAMA
- 06
Investigational Fentanyl Vaccine Enters Human Trials
An investigational fentanyl vaccine has commenced human trials, aiming to prevent overdose and treat addiction. If proven safe and effective, this vaccine could represent a significant advancement in addressing substance use disorders. The development is particularly relevant for healthcare providers managing patients affected by opioid addiction.
via JAMA
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.